Health Economics›Breast cancer›Neoadjuvant chemotherapy, sequential regimens

Neoadjuvant chemotherapy, sequential regimens

Breast cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
D-FEC+Bev Variant #01	—	R 62 369	21d	—	—	—	—	—
D-AC+Bev Variant #01	—	R 31 410	21d	—	—	—	—	—
nP-EC Variant #01	—	R 21 147	21d	—	—	—	—	—
D-FEC Variant #01	—	R 5 123	21d	—	—	—	—	1
EC-D Variant #01	—	R 4 860	21d	—	—	—	—	1
T-EC Variant #01	—	R 3 974	28d	—	—	—	—	—
AC-D Variant #01	—	R 3 477	21d	—	—	—	—	2
T-FEC Variant #01	—	R 3 449	21d	—	—	—	—	—
EC-T Variant #01	—	R 3 315	21d	—	—	—	—	2
ddT-EC Variant #01	—	R 3 315	21d	—	—	—	—	—
EC-ddT Variant #01	—	R 3 315	21d	—	—	—	—	—
D-AC Variant #01	—	R 2 787	21d	—	—	—	—	—
AC-T Variant #01	—	R 1 931	21d	—	—	—	—	2
T-FAC Variant #01	—	R 1 291	21d	—	—	—	—	—
T-AC Variant #01	—	R 1 272	21d	—	—	—	—	—

15 of 15 regimens shown